Synthetic Antibody Mimics (SyAMs)


Synthetic Antibody Mimics (SyAMs) are bispecific molecules that directly engage immune effector cells to destroy cancer cells. They are comprised of an optimized immune cell-binding domain linked to a highly specific tumor-binding domain. Versatile, modular design enables Kleo to rapidly generate new SyAMs capable of mediating multiple types of interactions between tumor cells and the immune system.


How SyAMs Work

SyAMs function similar to bispecific biologic by linking cancer cells with immune effector cells of the innate and adaptive immune system. SyAMs attach to immune cells already present in the patient's body and the tumor micro-environment and target them against tumor cells, triggering an immune response that leads directly to killing of the tumor cell.

Platform Advantages

Similar to biologics, SyAMs directly engage patients’ immune system to destroy cancer cells by connecting target cancer cells with components of the immune system. However, compared to biologics, SyAMs are more versatile in that they are smaller and more tunable. They have potential to be safer and more effective because they are non-immunogenic and can attach to a wider range of binding sites on tumor cells. They are fully synthetic and modular in design, making them much faster and less costly to produce compared to biologics.